Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sac-TMT + Fruquintinib in Advanced Gastric/GEJ Adenocarcinoma
NCT07689292Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2026
- Primary completion
- Aug 2027
01
Overview
A Phase 2 trial of sacituzumab tirumotecan, fruquintinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecanfruquintinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07689292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07689292.